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Abstract: Malaria, caused by Plasmodium falciparum and related parasites, is responsible for
millions of deaths each year, mainly from complications arising from the blood stages of its life
cycle. Macrophage migration inhibitory factor (MIF), a protein expressed by the parasite during
these stages, has been characterized in mammals as a cytokine involved in a broad spectrum of
immune responses. It also possesses two catalytic activities, a tautomerase and an
oxidoreductase, though the physiological significance of neither reaction is known. Here, we have
determined the crystal structure of MIF from two malaria parasites, Plasmodium falciparum and
Plasmodium berghei at 2.2 A ˚ and 1.8 A ˚ , respectively. The structures have an a/b fold and each
reveals a trimer, in agreement with the results of analytical ultracentrifugation. We observed open
and closed active sites, these being distinguished by movements of proline-1, the catalytic base in
the tautomerase reaction. These states correlate with the covalent modification of cysteine 2 to
form a mercaptoethanol adduct, an observation confirmed by mass spectrometry. The Plasmodium
MIFs have a different pattern of conserved cysteine residues to the mammalian MIFs and the side
chain of Cys58, which is implicated in the oxidoreductase activity, is buried. This observation and
the evident redox reactivity of Cys2 suggest quite different oxidoreductase characteristics. Finally,
we show in pull-down assays that Plasmodium MIF binds to the cell surface receptor CD74, a
known mammalian MIF receptor implying that parasite MIF has the ability to interfere with, or
modulate, host MIF activity through a competitive binding mechanism.
Keywords: macrophage migration inhibitory factor (MIF); malaria; crystal structure; tautomerase;
oxidoreductase
Introduction
Plasmodium falciparum is responsible for 300–500
million cases and 1–3 million deaths from malaria
each year, mainly in sub-Saharan Africa,
1 making it
one of the main causes of mortality in the world. More
than 40% of the world’s population are living in areas
where malaria is transmitted, meaning around two bil-
lion people are at risk of contracting the disease.
2 The
main causes of mortality are complications due to
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life cycle is complicated, spanning both human and
mosquito hosts, but the clinical manifestations of the
disease are a result of the human blood stage cycle in
which the parasite invades red blood cells and prolifer-
ates asexually.
Patients with severe malarial anemia demonstrate
ineffective erythropoiesis.
3 It has been proposed that
some pathogenic manifestations of severe malaria,
such as anemia, could be brought on by the release of
proinflammatory cytokines by host macrophages in
response to infection by the parasite.
4 The proinflam-
matory cytokine, macrophage migration inhibitory fac-
tor (MIF) has been identified as one such host-derived
factor that inhibits erythropoiesis
3,5 and which there-
fore could contribute to severe malaria.
MIF was one of the first cytokines to be identi-
fied.
6,7 Originally described as an immune mediator
isolated from T-lymphocytes that inhibit the random
migration of macrophages,
8 it has over the years, been
implicated in many other processes of the innate and
adaptive immune responses. For example, MIF is the
only cytokine known to counter-regulate the immuno-
suppressive effects of glucocorticoids.
9 It is released by
proinflammatory stimuli such as lipopolysaccharides,
toxic shock syndrome toxin 1, and malaria parasites.
10
The proinflammatory properties of MIF contribute to
the pathogenesis of several diseases such as severe
sepsis, acute respiratory distress syndrome, asthma,
inflammatory bowel disease, and the autoimmune dis-
eases rheumatoid arthritis, and glomerulonephritis.
11
Indeed, neutralization of MIF by anti-MIF antibodies
has been shown to be therapeutically beneficial to
patients with various proinflammatory diseases.
12–16
There is also evidence to suggest that MIF is involved
in cancer,
17,18 diabetes,
19 and multiple sclerosis.
20 As
well as regulating glucocorticoid activity, MIF is
involved in a wide range of cellular processes, includ-
ing transcriptional regulation of inflammatory gene
products, cell cycle control, modulation of cell cycle
proliferation and differentiation, inactivation of the tu-
mor suppressor factor p53, and signal transduction. A
classic cytokine receptor has not yet been identified
for MIF and CD74,
21 CXCR2,
22 the Jun activation do-
main binding protein (Jab-1),
23 and the ribosomal
protein S19
24 are the only functional MIF-binding pro-
teins to have been described.
MIF is notable among cytokines in having two
catalytic activities. The first, a keto-enol tautomerase
activity, is mediated by a conserved N-terminal pra-
line.
25 The second, an oxidoreductase activity,
26 is
associated with a thioredoxin-like motif. The physio-
logical substrates for the two enzyme activities remain
unknown as does their biological function. In crystals,
mammalian MIF is a homotrimer with the tautomer-
ase active site situated at the interface between pairs
of subunits.
27 The tautomerase active site, lined by res-
idues 1, 33–34, 64–66 (Fig. 1), is highly conserved
among MIF homologues. The residues necessary for
the protein-thiol oxidoreductase activity, which is asso-
ciated with a CXXC motif in mammalian MIF, are less
conserved with only a single cysteine present in the
corresponding region of Plasmodium MIF. However,
Plasmodium MIF retains both catalytic activities but
at about 20% specific activity compared with recombi-
nant human MIF.
29
The single MIF homologue in Plasmodium was
identified through the sequencing of the parasite ge-
nome.
30 Subsequently, three studies have been pub-
lished with a more detailed analysis of Plasmodium
MIF.
29,31,32 It is expressed in all life cycle stages and is
localized to both the parasite and the host cytoplasm
in the intracellular blood stage forms. Transcription
levels peak at the late trophozoite blood stage.
29 Like
mammalian MIF, which is secreted via nonclassical
pathways, Plasmodium MIF lacks a secretion signal. It
is likely that it is released from infected red blood cells
during schizont rupture and merozoite release.
29 Para-
site derived MIF has been detected in the serum of
patients infected with P. falciparum.
32 In vitro experi-
ments showed a decrease in the cell surface markers
TLR2, TLR4, and CD86 in response to Plasmodium
MIF exposure.
31 Although MIF is not essential for par-
asite survival, there is an increase in the number of
circulating reticulocytes in animals infected with
PbMIF knockout parasites,
29 in agreement with other
studies
3,5,10,33–35 which found that host MIF inhibits
erythropoiesis.
In earlier work, we have determined structures of
proteins important in redox regulation in P. falcipa-
rum.
36,37 To better understand the functional role of
macrophage MIF in malaria, including its redox signif-
icance, we determined the crystal structures of P. ber-
ghei and P. falciparum MIF (PbMIF and PfMIF,
respectively). Additionally, as an indication of mecha-
nism of action of Plasmodium MIF, we determined its
ability to bind to one receptor for mammalian MIF,
the cell surface determinant CD74.
Results
Protein expression and characterization
Following purification of the recombinant Plasmodium
MIFs, MALDI mass spectrometry was performed on
each sample. The molecular mass of PbMIF was meas-
ured as 14,091 Da. This compares with the predicted
mass of 14,013 Da, the difference being satisfactorily
accounted for by the covalent attachment of a mole-
cule of b-mercaptoethanol (78 g mol
 1). The presence
of the b-mercaptoethanol species was later confirmed
by the crystal structure (see later). The calculated mass
of PfMIF is 13,924 Da and so the two observed molec-
ular mass peaks of 13,931 and 14,007 Da correspond
to the native protein and a b-mercaptoethanol adduct,
respectively.
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The oligomeric state of MIF has been the subject of
debate with suggestions that the active species is vari-
ously a monomer, a dimer, or a trimer.
38 The two
Plasmodium MIFs appeared to be trimers in vitro
from their gel filtration characteristics. Analytical
ultracentrifugation was performed to establish rigor-
ously the oligomerization state of PfMIF. Sedimenta-
tion equilibrium analysis showed the average molecu-
lar weight to be 40 kDa consistent with a trimer form
(calculated molecular weight 41.7 kDa). However, the
sample was heterogeneous. Velocity sedimentation
analysis revealed a predominant lower molecular
weight species with the mass of a trimer, and a three-
fold less abundant larger species with a mass five
times greater (Fig. 2). The combined results of the
equilibrium and velocity sedimentation experiments
therefore suggest that Plasmodium MIF consists
mainly of trimeric material with about 30% pentamers
of the trimer (i.e., 15-mers) in a non-, or very slowly
exchanging mixture. The observation of the higher
molecular weight species is interesting in the light of
an earlier attribution of chaperone-like activities to
MIF.
39
Although these results show that purified Plasmo-
dium MIF is predominantly a trimer, this is not neces-
sarily the physiologically relevant oligomeric state of
the protein. For example, MIF may be stored in the
trimeric form but dissociate on release from the cell.
Extracellular concentrations of MIF range from 4 ng
mL
 1 in normal blood plasma to 150 ng mL
 1 in
patients with septic shock,
40 values that are much
lower than the concentrations used for these experi-
ments. At these 1000-fold lower concentrations, it is
possible that the trimer dissociates and that extracellu-
lar Plasmodium MIF is monomeric or dimeric.
Three-dimensional structure of Plasmodium MIF
The crystal structures of PbMIF and PfMIF reveal an
identical polypeptide chain topology to human MIF.
Each protomer consists of a four-stranded b-sheet (b2-
b1-b3-b4) onto one face of which are packed two anti-
parallel a-helices [Fig. 3(A,B)]. There is a pseudo two-
fold axis of symmetry within the subunits of both MIF
Figure 1. Amino acid sequence alignment of parasite and mammalian MIFs. The figure was generated in ESPript
28 and
adjusted manually to optimize the structure-based alignment. Black shading highlights invariant residues in the alignment
whereas boxed residues are conserved. Key catalytic residues for the tautomerase activity are highlighted with an asterisk
below the alignment. The conserved CFVR motif (highlighted in gray, first cysteine with a triangle) in the Plasmodium MIFs is
replaced by a CALC motif in the mammalian MIFs (also highlighted in gray). GenBank
TM accession codes for the sequences
are as follows: Human: Q6FHV0, Sheep: Q1ZZU7, Pig: P809028, Cow: P80177, Plasmodium falciparum: Q8I5C5, P. berghei:
Q4YQW0, P. yoelii: Q1HEA2, P. chabaudi; Q4Y5M8, P. vivax: A5K093, P. knowlesi; B3LCT3, Toxoplasma gondii: A1XDS9,
Brugia malayi: A8PJU3, Leishmania major: 3B64_A. The secondary structure elements of PfMIF and huMIF (1MIF.pdb) are
shown above and below the alignment respectively.
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ments b1 (residues 2–7), b2 (39–44), and a1 (13–31) to
b3 (58–63), b4 (96–100), and a2 (72–88). These ele-
ments of the structure can be superposed with a root
mean squared displacement (rmsD)i nC a positions of
1.7 A ˚. Least squares superposition of the two P. ber-
ghei protomers and six P. falciparum MIF subunits
gives average pairwise rmsD values in the range 0.9–
1.2 A ˚ [Fig. 3(C)]. The secondary structure elements
superimpose closely with the largest differences occur-
ring in the loop regions, residues 31–37 and 64–70,
where the electron density is less well defined.
The C-terminal residues (102–114 together with
the poly-His tag) are not defined by the electron den-
sity maps for either chain of PfMIF and these residues
are assumed to be disordered. In PbMIF the chain is
defined up to residue 114 and it is seen that the C-ter-
minal residues extend away from the core of the subu-
nit to pack onto an adjacent protomer in the trimer
[Fig. 3(C,D)]. Residues 104–107 form a segment of b-
strand, b5, which aligns in an antiparallel fashion with
b4 of the neighboring subunit so that in the trimer the
three b-sheets form a discontinuous b-barrel. A solvent
channel coincident with the molecular three-fold axis
runs through the center of the assembly. The channel
is a feature of all published MIF structures but its bio-
logical function, if any, is unknown. Equivalent Ca
atoms of the PfMIF and PbMIF trimers can be super-
imposed with an rmsD of 1.1 A ˚, the principal differen-
ces again lying in loop regions. As expected, the Plas-
modium MIF trimers are very similar in structure to
that of the human homologue
25,42–47 with an average
rmsD between huMIF (1CA7
25) and PbMIF of 2.6 A ˚,
and between huMIF and PfMIF of 2.2 A ˚ [Fig. 3(E,F)].
The tautomerase active site
The tautomerase active site has been defined in human
MIF by the determination of crystal structures of com-
plexes with the substrate p-hydroxyphenylpyruvate
(HPP)
25 and a competitive inhibitor 2-fluoro p-
hydroxycinnamate.
48 In each structure, three ligand
molecules are bound per trimer each located at a sub-
unit interface in hydrophobic cavities that contain the
catalytic base, Pro1. Besides the N-terminal proline,
the important substrate binding residues are Lys32,
Ile64, Tyr950, and Asn970, where the apostrophes sig-
nify residues from the neighboring subunit.
25 These
residues are conserved among the mammalian MIFs
(Fig. 1). Comparison of the active site region of unli-
ganded huMIF and huMIF bound to HPP with the
corresponding region of PbMIF, following least
squares superposition of the respective chains, reveals
a noticeable difference in the position of Pro1, the cat-
alytic proline. It is shifted  3A ˚ further into the active
site, partially filling the volume that is occupied by the
HPP molecule in the huMIF-substrate complex [Fig.
4(A,B)]. Pro1 in PbMIF is in van der Waals contact
with Tyr96, a residue whose side chain in huMIF
packs over the aromatic ring of the HPP from the op-
posite face of the cavity. This Pro1-Tyr96 interaction
effectively closes off the active site in PbMIF [Fig.
4(A,B)]. Interestingly, the two protomers in the asym-
metric unit in the PfMIF crystal exhibit different con-
formations of Pro1. In chain B, the electron density
maps define Pro1 in a position that superimposes with
that in PbMIF, whereas in chain-A they reveal the pro-
line in a location reminiscent of that in huMIF [Fig.
4(B)], giving rise to an open active site cavity as
observed for huMIF.
Figure 2. Analytical ultracentrifugation of PfMIF. A solution of PfMIF at a concentration of 2.6 mg mL
 1 was serially diluted in
50 mM Tris, 200 mM NaCl, 5% glycerol to give PfMIF/2 (1.3 mg mL
 1), PfMIF/4 (0.65 mg mL
 1), PfMIF/8 (0.33 mg mL
 1), and
PfMIF/16 (0.16 mg mL
 1) samples. The velocity sedimentation experiment was conducted at 35,000 rpm over 4 h and the
absorbance was plotted against the apparent MW. The results show that in solution PfMIF is predominantly trimeric with a
small percentage of species at five times this MW.
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with other changes that distinguish the ‘‘closed’’ active
sites of the two PbMIF trimers and trimer B of PfMIF
(PfMIF-B) from the ‘‘open’’ active sites of the huMIF
trimer and the trimer formed from the PfMIF A chains
(PfMIF-A). First, and as discussed in more detail later,
Cys2 is covalently modified in PbMIF and PfMIF-B by
disulphide linkage to a molecule of b-mercaptoethanol
[Fig. 4(C)]. In PfMIF-A, there is no such covalent
modification. The distinguishing feature of this proto-
mer is the presence of two molecules of glycerol
located at the entrance to the substrate binding cavity.
Second, Ile65 in PbMIF and PfMIF-B is flipped
out of the active site with its main chain amide group
displaced by 1.2 A ˚ so that it is out of hydrogen bond-
ing distance of the carboxyl group of the HPP moiety
observed in huMIF. Third, the aromatic ring of Tyr95
in huMIF lies perpendicular to that of HPP so as to
form favorable p-stacking interactions with the sub-
strate. In PbMIF and PfMIF-B, the corresponding ring
of tyrosine 96 is displaced from, and has a parallel ori-
entation with respect to, the aromatic ring of HPP
[Fig. 4(B)]. This suggests either that HPP has a differ-
ent mode of binding in Plasmodium MIF compared
Figure 3. Structure of Plasmodium MIF. A: Topology diagram of the Plasmodium berghei MIF subunit with strands shown as
yellow arrows and helices as red cylinders. The secondary structure elements are numbered. The amino (N) and carboxyl (C)
termini are indicated. The pseudosymmetry relating b-strands 1 and 2 and a-helix 1 and b-strands 3 and 4 and a-helix 2 is
apparent. B: Ribbon diagram of the PbMIF subunit with secondary structure elements colored as in (A). C: Overlay of the
P. berghei (blue) and P. falciparum (yellow) MIF subunits showing the high structural similarity between the two proteins. The
C-terminal residues of PfMIF are disordered and missing from the model. D: The PbMIF trimer viewed down the molecular
three-fold axis with subunits colored individually in yellow, green, and blue. E: Overlay of the MIF subunits from P. berghei
(blue) and human (magenta). F: Overlay of the MIF trimers from P. berghei (blue) and human (magenta) showing the close
superposition of the b-sheets and the slight variation in the orientation of the a-helices. These and subsequent images were
produced in CCP4MG.
68
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changes take place in PbMIF and PfMIF-B to generate
the catalytically active state.
Receptor interactions
CD74 has been identified as a cell surface receptor for
huMIF.
49 We used ConSurf
50 to determine clusters of
conserved residues on the Plasmodium MIF trimer
surface that might represent a CD74 binding site. As
expected, the highly conserved residues cluster princi-
pally around the tautomerase active site (data not
shown). To establish whether Plasmodium MIF inter-
acts with CD74 we investigated the protein–protein
interaction by GST-pulldown. Since in our hands full
length CD74 failed to express in useful amounts, we
expressed and purified the mouse CD74 ectodomain
Figure 4. The tautomerase active site. A: Comparison of the human (left), P. berghei (center) and P. falciparum chain-A (right)
MIF active site cavities. In the PbMIF and PfMIF images, the HPP substrate is taken from the huMIF coordinate set following
superposition with the ligand-bound form of this protein. In huMIF and PfMIF chain-A, the active site is ‘‘open,’’ whereas in
PbMIF, it is ‘‘closed’’ and there is a steric clash between the protein and the HPP moiety. The proteins are shown as
electrostatic surfaces highlighting the fact that in Plasmodium MIF the active sites are more negatively charged than that of
huMIF. B: Stereo view of the active site of MIF. The human (magenta), P. berghei (blue), and P. falciparum chain-A (yellow)
MIFs have been superposed and the active site residues are shown in the context of the tautomerase substrate, HPP
(colored by atom type C, green; O, red) bound to huMIF. Pro1 of human-MIF and PfMIF-A are in equivalent positions but
Pro1 of PbMIF is markedly displaced. In both the Plasmodium MIFs, the aromatic ring of Tyr96 is in a perpendicular plane to
that of this tyrosine in the huMIF active site. C, D: Electron density maps displayed in the vicinity of residue 2 of PbMIF chain
C and PfMIF chain-A, respectively. The position 2 side chain was truncated to Ala and cycles of REFMAC refinement were
carried out prior to the calculation of 2Fo-Fc (blue) and Fo-Fc (green) maps which are displayed at the 1.0 and 3.0 r levels
respectively and displayed on the final refined models. The covalent modification of Cys2 in the PbMIF chain and the dual
conformation of the Cys2 side chain in PfMIF chain-A are evident.
Dobson et al. PROTEIN SCIENCE VOL 18:2578—2591 2583(residues 51–279) containing all the elements known
to interact with huMIF fused to GST. As shown in
Figure 5, the mouse CD74 ectodomain fused to GST
(Lane 4) readily pulled down recombinant PbMIF-his6
relative to a GST control (Lane 1). To determine if the
stability of this interaction was sensitive to the pres-
ence of the tautomerase substrate, we repeated the
assay in the presence of 1, 10, and 25 mM HPP. Addi-
tion of HPP at concentrations up to 10 times the
KM(HPP) of huMIF had a negligible effect on CD74
binding (Lanes 5 and 6). Similar results were obtained
for PfMIF (data not shown).
Covalent modification of Cys2
In the six subunits of the asymmetric unit of PbMIF
and in one of the two subunits (PfMIF-B) of the asym-
metric unit of PfMIF, we observed prominent and
unexpected electron density features extending from
the side chain of Cys2 [Fig. 4(C)]. In contrast, the elec-
tron density at position 2 of PfMIF chain-A (PfMIF-A)
defines the expected cysteine residue, albeit one with a
dual conformation [Fig. 4(D)]. The size and shape of
the electron density associated with the additional fea-
ture [Fig. 4(C)] prompted us to infer that there was a
straight chain species in a disulphide linkage to Cys2.
The presence of b-mercaptoethanol in the protein stor-
age buffer together with the mass spectrometry results,
which showed m þ 76 and m þ 78 peaks, led to the
conclusion that Cys2 was covalently linked to an
ASACH2ACH2AOH species. In most of the chains,
there was evidence of dual conformations. In the more
prominent conformer, the extended position 2 side
chain extends into a hydrophobic pocket surrounded
by Met39, Asn41 and Glu4 and Ile60, Leu480 and
Phe590 from the neighboring subunit. In the lower
occupancy conformation, the modified Cys2 residue is
stabilized by polar interactions between its OH group
and Arg610 and Glu980. The covalent modification of
Cys2 is linked to a 1.4 A ˚ displacement of the position
2C a atom relative to its position in PfMIF-A, which
correlates with the movement of the Pro1 residue and
the closure of the active site.
The C-terminus
It was recently reported that deletion of residues 105–
114 at the C-terminus of MIF results in abolition of
the tautomerase activity.
51 Although the C-terminal
residues are important for tautomerase substrate bind-
ing, they form no direct interactions with the HPP
moiety and it is logical to conclude that the impor-
tance of the C-terminus, for the tautomerase activity,
is through its effect on trimer stability. The sequence
of this segment is reasonably well conserved (Fig. 1)
and in the structure these residues are involved in
interactions between subunits in forming the trimer.
The crystal structures of human and rat MIF
25,46,52 are
closely similar except that the C-terminal residues of
rat MIF are disordered. This difference recurs in the
Plasmodium structures in which the C-terminus is
fully ordered in the PbMIF protomers, but disordered
in PfMIF beyond residues Asp101 and Asn106 of
chains A and B, respectively.
The intersubunit interactions in the Plasmodium
MIFs were analyzed using the program PISA.
53 In
PbMIF, a total of 2674 A ˚2 of solvent accessible surface
becomes buried on formation of the trimer compared
with only 1539 A ˚2 in PfMIF, where the C-terminal res-
idues are missing. Although the PfMIF trimer appears
to be less thermodynamically stable than the PbMIF
trimer, both molecules are evidently trimeric. In
PbMIF, residues 107–112 interact with residues 92–99
of the adjacent subunit. Residues spanning Phe107 to
Ser112 of one subunit form main chain hydrogen
bonds with b4 of the adjacent protomer to make the
additional b-strand [Fig. 6(A)].
The oxidoreductase active site
In huMIF, the oxidoreductase activity is associated
with a conserved motif, C
56ALC
59. A C56S mutant
retains 55 and 68% wild-type activity for insulin and
2-hydroxyethyldisulphide (HED) reduction, respec-
tively, whereas the C59S mutation completely abol-
ishes these activities.
26 In the Plasmodium MIFs, the
motif is not conserved and the corresponding residues
are C
58FVR
61. In the crystal structures, this motif is
quite differently structured [Fig. 6(B)]. Cys58 of Plas-
modium MIF is the first residue of strand b3 and its
side chain together with that of Val60 are buried in
the hydrophobic core of the molecule [Fig. 6(B)].
Phe59 and Arg61 are on the opposite face of this b-
strand and contribute to the subunit interface. In
huMIF, Cys56 lies in the loop region preceding b3 and
Figure 5. GST-pulldown showing CD74–PbMIF interaction.
Left hand lane: 1% input PbMIF; Lanes 1–3: background
binding to GST loaded glutathione sepharose beads with 1,
10, and 25 mM HPP, respectively; Lanes 4–6: PbMIF
binding to GST-CD74 loaded glutathione sepharose beads
with 1, 10, and 25 mM HPP, respectively. The masses in
kDa of molecular markers are indicated at the left.
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may form in the CALC region on oxidization.
26
Discussion
The cytokine macrophage MIF has a widespread distri-
bution with homologues in Plasmodium, Leishmania,
Toxoplasma, and parasitic nematodes. The absence of
MIF in other protozoans indicates that the expression
of MIF in unicellular eukaryotes is confined to para-
sites that engage in interactions with host cells in the
blood. Given the established role of MIF in the
immune system, it may be that differences between
the parasite and host MIF proteins are important for
progression of parasitemia and evasion of the host
immune response. MIFs from protozoan parasites
have previously been structurally and functionally
characterized for the parasitic nematodes Brugia
malayi,
54 Ancylostoma ceylanicum,
55 and the apicom-
plexan Leishmania major.
56
The tertiary and quaternary structures of the P.
falciparum and P. berghei MIFs determined here are
similar to one another and to the mammalian and par-
asite MIFs. Electrostatic surface analysis reveals that
the tautomerase active site of Plasmodium MIF has
more negatively charged character than huMIF [Fig.
4(A)], a phenomenon also observed in the L. major,
56
and hookworm
55 structures. The extra negative charge
is attributable to Glu98; which replaces Asn97 in the
human homologue. The differences observed in the
active site, in terms of electrostatic potential and the
conformation of catalytic residues, may account for
why Plasmodium MIF has a lower tautomerase spe-
cific activity toward HPP than huMIF.
29,32 It may also
point to different substrate specificity, given that the
physiological substrate has yet to be identified.
Receptor interactions
CD74 has been identified as a cell surface receptor for
huMIF
49 and our results suggest this interaction is
Figure 6. Quaternary interactions in Plasmodium MIFs and distribution of cysteines in huMIF and PbMIF. A: The P. berghei
MIF trimer illustrating the extensive intersubunit interactions of the C-terminal residues. Two of the subunits are represented
as ribbons (blue and light blue) with the C-terminal amino acid residues (Ser103-Gly114) drawn as bonds and colored by
atom type (C, green; N, blue; O, red). The third subunit is shown as a surface whose color indicates the electrostatic potential
with red (negative) blue (positive) and white/gray (neutral). The hydrophobic nature of the interface is apparent. B: Surface
rendering of single protomers taken from the trimers of huMIF (left) and PbMIF (right). The cysteine and CME residues
together with the residues of the CALC and CFVR motifs are shown in cylinder format and colored by atom type (C, green; N,
blue; O, red). The Cys/CME residues are shown with a yellow surface. Cys58 of Plasmodium MIF is completely buried within
the protomer.
Dobson et al. PROTEIN SCIENCE VOL 18:2578—2591 2585conserved in the Plasmodium MIFs. Although better
defined in its intracellular form, it is known that 2–5%
of the CD74 protein localizes to the cell surface.
57 The
NMR structure of the CD74 ectodomain is trimeric,
58
sharing the three-fold rotational symmetry of MIF.
The programme ConSurf
50 shows that highly con-
served residues on the Plasmodium MIF trimer sur-
face cluster around the tautomerase active site. A pos-
sible coincidence/overlap of the CD74 binding surface
and the tautomerase active site has recently been
inferred for huMIF following the observation that
antagonists of the huMIF-CD74 interaction also inhibit
the tautomerase activity of the enzyme.
59 This
prompted us to investigate the influence of the HPP
substrate on Plasmodium MIF—CD74 interaction.
Although the mouse CD74 ectodomain was able to pull
down recombinant histidine tagged Plasmodium MIF,
we found no significant effect of the presence of HPP,
even at concentrations up to 10 times the KM for HPP
of huMIF, on the interaction with CD74. The fact that
saturating concentrations of the tautomerase substrate
do not inhibit CD74 binding leads to the tentative sug-
gestion that the tautomerase active site and the CD74
binding epitope are nonoverlapping.
Implications for oxidoreductase mechanism
One of the most interesting aspects of the structures
described here is the modification of Cys2, where the
presence of disulphide-linked mercaptoethanol adducts
is clearly indicated by the electron density maps. The
modified residue S,S-(2-hydroxyethyl)thiocysteine
(CME) is present in the six crystallographically inde-
pendent subunits of PbMIF and in one of the two crys-
tallographically independent subunits of PfMIF. There
is no evidence of covalent modification of the three
other cysteine residues (Cys3, Cys58, or Cys102) in ei-
ther structure, indicating that Cys2 is uniquely
reactive.
Oxidoreductase activity in mammalian MIFs was
first considered when the existence of the well-con-
served CALC motif was correlated with the presence of
CXXC motifs at the catalytic centers of thiol-protein
oxidoreductases such as thioredoxin.
26 The reaction
cycles of thioredoxin-type oxidoreductases feature
intermolecular disulphide bonds with substrate pro-
teins and intramolecular disulphide bonds between the
adjacent cysteines of the motif.
60 HuMIF was subse-
quently shown to exhibit oxidoreductase activity to-
ward insulin and 2-hydroxyethyl disulphide (HED)
substrates.
26 In huMIF, site-directed mutagenesis
showed that the second cysteine (Cys59) of the CALC
motif is essential for oxidoreductase activity, whereas
serine substitution of the first cysteine led to quite
modest reductions in rate. The location of the CALC
motif in the huMIF structure suggests that the oxidor-
eductase reaction could only plausibly be mediated by
the monomeric form. In the trimer, neither of the
CALC motif cysteine residues (at positions 56 and 59)
nor cysteine 80 is surface accessible. In the monomer,
Cys59 and 80 would be on the surface of the protein
[Fig. 6(B)].
Since HED reduction produces two molecules of
b-mercaptoethanol, the Cys2 adducts observed here
could represent intermediates in the Plasmodium
MIF-catalyzed reduction of this substrate. This would
imply a quite different mechanism of action from that
proposed for human MIF consistent with the strikingly
different pattern of cysteine residues in the Plasmo-
dium MIF sequences and the absence of the CXXC
motif. In the Plasmodium proteins, cysteines are con-
served at positions 2, 3, 58, and 102 (Fig. 1), in con-
trast to the mammalian MIFs where the conserved
cysteines occur at 56, 59, and 80. Although, Cys58 in
Plasmodium MIF and Cys56 in huMIF are corre-
sponding residues in the sequence alignment (Fig. 1),
the structures reveal quite different environments. In
contrast to Cys56 in huMIF, which would be surface-
exposed in the monomeric form, the Cys58 side chain
in Plasmodium MIF is buried in the hydrophobic core
of the subunit and clearly incapable of participating in
redox reactions in the absence of major conforma-
tional changes in the protein [Fig. 6(B)].
The Plasmodium MIF oxidoreductase activity was
shown in a previous study to be very low. In this
work, we found that the activity of wild-type PfMIF
against HED was scarcely above background levels,
and much lower than that of recombinant human glu-
taredoxin 1, which was used as a positive control (data
not shown). This very low activity prevented us from
evaluating the catalytic contribution of cysteine-2 by
site-directed mutagenesis. The uniquely reactive char-
acter of Cys2 is unexplained and may be associated
with uncharacterized chemistry in MIF possibly
involving the adjacent active site proline, Pro1.
The cytokine activity of MIF
The CC motif at the N-terminus of Plasmodium MIF
(Cys2-Cys3) is a recognized motif in one of the four
chemokine families. As Plasmodium MIF has been
characterized as a cytokine, it throws up the possibility
that it could mediate some of its activity via this CC
motif. Although, there is no evidence of disulphide
bonds in the Plasmodium MIF crystal structures, the
subunit does exhibit a high degree of structural simi-
larity to the dimeric form of interleukin-8 (IL-8), a
CXC chemokine. There is also evidence that MIF is a
noncognate ligand of the CXC chemokine receptor
CXCR2 that is known to bind IL-8.
22 In the same
study, it was pointed out that huMIF may qualify as a
pseudo-CXC or DC chemokine, given its lack of C-ter-
minal cysteines.
22 Plasmodium MIF has a C-terminal
cysteine (Cys102) that is absent in huMIF, which may
indicate that it has added chemokine functionality that
could differentiate the two homologues during parasite
invasion. An added complexity is that activation of
CXCR2 by IL-8 requires an N-terminal ELR motif, of
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two nonadjacent but adequately spaced Asp and Arg
residues. In Plasmodium, MIF Glu55 and Arg93 are
surface exposed and spaced such that they could
mimic the ELR motif of IL-8.
Conclusion
The role of Plasmodium MIF in the human host is lit-
tle understood. Human MIF is known to have a role in
multiple immune pathways and its function/dysfunc-
tion is associated with a multitude of diseases. The
malaria parasite releases MIF during the blood stage
cycle of infection when it would seem counter-produc-
tive to release a protein that could elicit a potentially
lethal host immune response. In presenting the crystal
structure of MIF from P. berghei and P. falciparum,i t
is hoped that the important differences, and indeed
similarities, between Plasmodium and human MIF
may provide an indication of how the parasite-derived
protein contributes to the progression of parasitemia.
There is a possibility that Plasmodium MIF could be a
potential drug target in malaria and it would therefore
be important to target the parasite protein selectively
relative to the host protein. MIF clearly has potential
for inhibitor design with huMIF having been the sub-
ject of a virtual screen for MIF-CD74 antagonists,
59
and the Plasmodium MIF structures presented here
provide a basis for extending this approach.
Materials and Methods
Plasmid preparation
Protein expression constructs were prepared by previ-
ously published protocols.
29 Briefly, the coding sequen-
ces for P. falciparum (PlasmoDB entry: PFL1420w)
and P. berghei (GeneDB entry: PB000372.03.0) MIF
were amplified from mixed blood stage cDNA using the
primers 50-AAAATTTCCGCATGCCTTGCTGTGAAGTAA
TAAC-30 and 50-ATTGGATCCGCCGAAAAGAGAAC
CACTGAAGCG-30 for P. falciparum and 50-AAATTT
CCGCATGCCGTGCTGTGAATTAATAAC-30 and 50-
ATTGGATCCACCAAATAGTGAGCCACTAAAAGC-30 for
P. beghei (italicized bases indicate restriction sites).
The PCR products were digested with SphI and BamHI
and ligated into the similarly digested pQE-70 (QIA-
GEN) expression vector such that recombinant protein
products were expressed with a C-terminal His6-tag.
Constructs were sequenced to confirm MIF sequence
identity.
Protein expression and purification
PfMIF and PbMIF were expressed in E. coli BL21star
(Novagen) cells grown on Luria Broth (10 g tryptone,
5 g yeast extract, 10 g NaCl per liter). Bacteria were
grown to an optical density at 600 nm of 0.6 before
addition of isopropyl-D-thiogalactoside to 1 mM to
induce expression of recombinant protein. Growth was
allowed to continue at 37 C for 4 h. Cells were har-
vested by centrifugation and resuspended and lysed in
50 mM Tris-HCl pH 8.0, 500 mM NaCl, 10% v/v glyc-
erol, 10 mM b-mercaptoethanol, 0.01% Nonidet P-40,
and complete cocktail protease inhibitor (Roche). The
lysate was cleared by centrifugation at 15, 000 rpm for
40 min at 4 C and loaded onto a 5 mL HisTrap
TM HP
chelating column (GE Healthcare) equilibrated in
buffer A (50 mM Tris-HCl pH 8.0, 200 mM NaCl,
10% v/v glycerol, 10 mM b-mercaptoethanol, 20 mM
imidazole). After a washing step, the bound proteins
were eluted over 10 column volumes with a 20–500
mM linear imidazole gradient in buffer A. The MIF-
containing fractions were identified by SDS-PAGE
analysis, concentrated, and loaded onto a Superdex
200 gel filtration column (Amersham Pharmacia)
equilibrated in 50 mM Tris pH 8.0, 200 mM NaCl, 5%
v/v glycerol, 5 mM b-mercaptoethanol. Following size
exclusion chromatography, the MIF proteins were
judged to be pure from the Coomassie blue staining
pattern following denaturing gel electrophoresis.
GST pulldowns
Pf and PbMIF-His6 were expressed and purified as
described previously.
29 The ORF of the CD74 ectodo-
main (residues 51-279) was amplified from mouse
cDNA using primers (L2809: 50-TGGGCAGGCTCATA
TGGCTTACTTCCTGTACCAGCAACAGG-30and L2808:
50-GCCTGGATCCTTACAGGGTGACTTGACCCAGTTCC-
30) and inserted (NdeI, BamHI, italicized in sequence)
into pRP265NB (described previously
61). The empty
vector pRP265NB (for control GST expression) and
the GST-CD74 expression plasmid were transformed
in BL21 (DE3) pLysS, bacteria were grown at 30 Co n
Luria Broth (LB, Q-biogene) containing 30 lg/mL
chloramphenicol and 0.05 lg/mL ampicillin. Protein
expression was induced at OD600 of 0.6 by the addi-
tion of isopropyl-D-thiogalactoside to a final concentra-
tion of 1 mM. After 5 h, the cells were harvested and
lysed in 50 mM Tris (pH 8.0), 500 mM NaCl, 5%
(vol/vol) glycerol, 0.01% Tween in the presence of
complete protease inhibitor cocktail (Roche) and 1 lg/
mL lysozyme. Genomic DNA was fragmented by soni-
cation, after which the lysate was cleared by centrifu-
gation at 30,000   g for 1 h at 4 C. Approximately 1
lg of GST or GST-CD74 in bacterial lysate was loaded
on glutathione sepharose 4b beads (GE Healthcare) by
rotating at 4 C for 1 h. After washing with PBS, Pf or
PbMIF-His6 was added to a final concentration of
roughly 4 lM in 500 lL binding buffer (50 mM
KxHyPO4 (pH 7.2), 50 mM NaCl, 5% glycerol, 0.01%
Tween) in presence or absence of substrate (p-hydrox-
yphenylpyruvyc acid, Sigma), which was added dis-
solved in DMSO. After 1 h binding at 4 C, the glutathi-
one beads were washed three times with binding
buffer, supplemented with the appropriate concentra-
tion of HPP, before loading on a 15% polyacrylaminde
gel. MIF-His6 was detected by western blotting with
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Analytical ultracentrifugation
Sedimentation equilibrium experiments were per-
formed on PfMIF with Dr. Andrew Leech (Molecular
Interactions Laboratory, Technology Facility, Depart-
ment of Biology, University of York) to determine the
oligomeric state of the protein. A Beckman Optima
XL/A analytical ultracentrifuge with an AN-50Ti rotor
was used to conduct the experiment using Beckman
cells. PfMIF was dialyzed overnight into 50 mM Tris-
HCl pH 8.0, 200 mM NaCl, 5% glycerol. Sample con-
centrations ranged from 2.6 to 0.16 mg/mL and were
prepared by serial two-fold dilutions. 115 lL protein
and 120 lL buffer was loaded into sample and refer-
ence channels, respectively. Initial absorbance scans
were taken at 3,000 rpm to verify that the cell con-
tents were evenly distributed before the speed was
increased and sedimentation equilibrium was reached.
Absorbance scans were taken at 3 h intervals and all
measurements were recorded at 293 K.
The distribution of material between species of
different oligomeric state was determined by velocity
sedimentation. Experiments were conducted using the
same material as for the sedimentation equilibrium
analysis. The cell contents were agitated so as to
destroy the concentration gradient and ensure even
distribution of material. A velocity run was then con-
ducted over 4 h at 35,000 rpm. The data from both
experiments were analyzed using HETANAL.
Protein crystallization
PfMIF and PbMIF were concentrated to 5 and 25 mg/
mL, respectively, for crystallization experiments. Suita-
ble crystallization conditions were initially screened in
96-well MRC Wilden crystallization plates using a
mosquito
V R (TTP LabTech) liquid handling robot to set
up nanoliter drops. Larger crystals were grown via the
hanging drop vapor diffusion method, where equal
volumes (1 lL) of protein and mother liquor were
mixed and allowed to equilibrate at room temperature.
PfMIF crystals grew from 0.2M KSCN, 10% PEG 8K,
10% PEG 1K, 100 mM Tris pH 8.0 and belong to
space group P213 with unit cell dimensions a ¼ b ¼ c
¼ 83.37 A ˚. PbMIF crystals grew from 0.2M KSCN,
13% PEG 6K, 100 mM Tris pH 8.5 and belong to space
group P21 where a ¼ 78.70 A ˚, b ¼ 69.17 A ˚, c ¼ 80.22
A ˚, and b ¼ 118.20 .
Crystals were soaked in mother liquor containing
25% glycerol as a cryoprotectant and rapidly cooled in
liquid N2 (110 K) for data collection.
Data collection and processing
Data for PfMIF and PbMIF were collected on beam-
lines ID14-2 and ID14-4, respectively, at the European
Synchrotron Radiation Facility (ESRF, Grenoble,
France) and were processed using the DENZO/SCALE-
PACK
62 and CCP4 packages.
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Determination of the structure of PbMIF
The structure proved difficult to solve by molecular
replacement (MR) with the P21 data with calculations
producing solutions that were inconclusive. All of the
MR programs tested aligned the trimeric three-fold
axis correctly but the rotation about this axis was very
uncertain (i.e., the translation function was good but
the subsequent rotation function was poor). In addi-
tion to the three-fold symmetry axis in the trimer,
each subunit has pseudo two-fold symmetry. Self-rota-
tion shows the crystallographic two-fold to be parallel
to the molecular three-fold, and perpendicular to the
pseudo two-fold axes, generating pseudo 222 symme-
try. Additionally, the Patterson map showed noncrys-
tallographic translation with a peak that was 43% of
the height of the origin peak at 0.50, 0.45, and 0.00.
This suggested that there were six molecules in the
Table I. Data collection and refinement statistics
P. berghei P. falciparum
Data collection
Space group P21 P213
Cell dimensions
a, b, c (A ˚) 78.70, 69.17,
80.22
83.29, 83.29,
83.29
a, b, c ( ) 90, 118.20, 90 90, 90, 90
Wavelength (A ˚) 0.94 0.933
Resolution (A ˚) 50–1.8 50–2.05
No. unique
reflections
72, 962 12,045
Rmerge 0.084 (0.610) 0.063 (0.393)
I/r(I) 17.35 (1.36) 34.6 (6.1)
Completeness (%) 99.6 (99.5) 99.9 (100)
Redundancy 4.0 (2.7) 14.2 (12.1)
Refinement
Resolution (A ˚) 40.78–1.78 58.90–2.05
No. reflections 68,494 12,045
Rwork/Rfree 0.20/0.25 0.25/0.32
No. atoms
Protein 5419 (including
CME)
1604 (including
CME)
Ligand GOL 48 GOL 12
Water 498 83
B-factors
Proteins 28.30 32.43
Ligand 43.86 47.96
Water 38.05 34.51
Rms deviation
Bond lengths (A ˚) 0.025 0.020
Bond angles ( ) 2.11 1.82
Rmerge, I/r(I), completeness and redundancy are given for all
data and for data in the highest resolution shell (numbers in
parentheses). Rmerge ¼ R|I –( I)|/RI, where I is the intensity
of an individual observation and (I) is the mean intensity of
the same reflection. Rfactor ¼ R||Fo|   |Fc||/R|Fo|, where Fo
are the observed and Fc the calculated structure factors. Rfree
was calculated using a test set of 5% of the data. CME is the
modified amino acid at position 2, S,S-(2-hydroxyethyl)-thio-
cysteine, and GOL is glycerol.
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cient of 2.24 A ˚3 Da
 1 (relating to a solvent content of
45%). All of this may have contributed to the difficulty
in finding an MR solution for the P21 data.
A partial solution was found using the automated
molecular replacement pipeline Balbes
64 following
reprocessing of the data in the space group P1. Sixteen
monomers were found using chain-A of coordinate set
2OS5
55 as the MR model. Of these, four protomers,
related in pairs by 120 , satisfied the symmetry opera-
tions for P21 with the expected pseudo translation. The
third chain of each trimer was generated and the sub-
sequent model was good enough to start refinement.
ARP/wARP was used to build in the P. berghei
sequence, refinement was performed with REFMAC,
65
and Coot
66 was used to finalize the model.
Determination of the structure of PfMIF
Data collected for PfMIF were processed in the cubic
space group P213. An ice ring forced the exclusion of
some data during processing. Initial molecular replace-
ment calculations using the human MIF coordinate set
(pdb entry 1GD0
45) as the search model were unsuc-
cessful most likely due to the low-sequence identity
between PfMIF and the human homologue ( 29%). A
solution was obtained when the PbMIF structure,
which had not been available initially, was used as the
model for molecular replacement with MolRep.
67 Two
protomers in the asymmetric unit were sought based
on the Matthews coefficient (1.73 A ˚3 Da
 1 with 29%
solvent content)
68 with the biologically relevant
trimers being generated via the crystallographic three-
fold axis. Data and refinement statistics for both struc-
tures are presented in Table I. PDB accession codes
are 2WKB and 2WKF for PbMIF and PfMIF,
respectively.
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